(NASDAQ:

) shares jumped 36.35% to $3.55 after the company reported the successful completion of an interim analysis of its Phase 3 trial of blisibimod in patients with Systemic Lupus Erythematosus.

(NYSE:

) shares surged 22.30% to $8.44 following announcement of collaboration with

(NYSE:

).

(NYSE:

) shares climbed 17.42% to $3.10 after the company raised its Q4 forecast. The company named David Dick as CFO and Marc Miller as COO.

(NASDAQ:

) shares jumped 15.63% to $8.15 after the company reported better-than-expected Q4 results.

(NYSE:

) climbed 13.33% to $135.04 after the company reported better-than-expected quarterly results and authorized a new share repurchase program.

(NYSE:

) shares gained 13.01% to $12.47 after the company reported a Q3 loss of $0.23 per share on revenue of $32.6 million.

(NASDAQ:

) shares surged 9.30% to $44.65 after the company reported upbeat Q4 results and issued a strong outlook.

(NYSE:

) gained 7.11% to $43.84 after the company reported upbeat Q4 earnings and issued a strong FY15 outlook.

(NYSE:

) shares rose 6.41% to $86.20 after the company reported better-than-expected earnings for the fourth quarter and raised its FY15 outlook.

(NASDAQ:

) shares surged 5.97% to $4.26 after the company reported Q2 results. Piper Jaffray initiated coverage on Unilife with a Overweight rating and a $10.00 price target.

(NASDAQ:

) rose 5.96% to $8.54 after the company reported a Q4 loss of $0.03 per share on sales of $6.6 million.

(NYSE:

) climbed 3.69% to $42.75 after the company reported better-than-expected earnings for the fourth quarter.

(NASDAQ:

) shares gained 3.20% to $37.68 after the company posted strong sales for the fourth quarter.